REGN 9933
Alternative Names: REGN-9933Latest Information Update: 22 Sep 2025
At a glance
- Originator Regeneron Pharmaceuticals
- Class Antithrombotics; Monoclonal antibodies
- Mechanism of Action Factor XI inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Venous thromboembolism
- No development reported Thrombosis
Most Recent Events
- 16 Sep 2025 Regeneron Pharmaceuticals plans a phase II ROXI-ATLAS trial for Atrial Fibrillation (Prevention) in October 2025 (NCT07175428)
- 09 Jul 2025 Regeneron Pharmaceuticals completes a phase I trial (In volunteers, Combination therapy) in United Kingdom (IV) (NCT06444178)
- 19 Dec 2024 Adverse events and efficacy data from the phase-II ROXI-VTE-I trial in Venous thromboembolism released by Regeneron Pharmaceuticals ,